Evaluation the Pharmacokinetics,Safety,Tolerability of Single Intravitreal Injection RC28-E in Subjects With Wet Age-Related Macular Degeneration
A Double-center, Open-label,Single Ascending Dose Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Intravitreous Injections of RC28-E (a Chimeric Decoy Receptor Trap Fusion Protein by Dual Blockage of VEGF and FGF-2) in Subjects With Wet Age-Related Macular Degeneration
Sponsor: RemeGen Co., Ltd.
Listed as NCT03777254, this PHASE1 trial focuses on Neovascular Age-related Macular Degeneration and remains completed. Sponsored by RemeGen Co., Ltd., it has been updated 8 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Oct 2021 — Jul 2024 [monthly]
Completed PHASE1
-
May 2021 — Oct 2021 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Jan 2021 — May 2021 [monthly]
Recruiting PHASE1
▶ Show 3 earlier versions
-
Apr 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Feb 2019 — Apr 2020 [monthly]
Recruiting PHASE1
-
Jan 2019 — Feb 2019 [monthly]
Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- RemeGen Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .